Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of Dotinurad on Serum Uric Acid Concentration in Chronic Kidney Disease Patients Treated with Febuxostat.
J Nippon Med Sch
September 2024
Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School.
Article Synopsis
- Febuxostat is effective for treating severe hyperuricemia in chronic kidney disease (CKD), and combining it with uricosuric agents like dotinurad may further lower uric acid levels.
- A study of 34 CKD patients showed that adding dotinurad to febuxostat increased uric acid excretion and reduced serum uric acid levels in patients with moderate kidney impairment (G3 and G4) but not in those with severe impairment (G5).
- The research highlights the need for further exploration of dotinurad's mechanisms to understand its role in managing uric acid levels in CKD patients.
Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study.
Rheumatology (Oxford)
September 2024
Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- The study aimed to compare the risk of kidney stones (urolithiasis) in gout patients starting treatment with allopurinol versus benzbromarone.
- Using a large national health database, researchers analyzed data from over 61,000 patients and found that those using allopurinol had a significantly lower incidence of kidney stones compared to those using benzbromarone.
- The results suggest that allopurinol is a safer option for gout management, especially in patients with high cardiovascular risk, which is important for healthcare providers to consider when prescribing treatments.
The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.
J Clin Med
February 2024
Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain.
(1) Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) increase uric acid excretion. The intensity of uricosuria is linked to glycosuria. (2) Methods: We aim to analyze the effect of SGLT2 inhibitors on urinary fractional excretion (FE) of uric acid and glucose in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in a single-center retrospective study with patients with T2DM and CKD who started on treatment with SGLT2is.
View Article and Find Full Text PDFPreventive Pharmacological Therapy and Risk of Recurrent Urinary Stone Disease.
Clin J Am Soc Nephrol
May 2024
Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan.
Background: Urinary stone disease is a prevalent condition associated with a high recurrence risk. Preventive pharmacological therapy has been proposed to reduce recurrent stone episodes. However, limited evidence exists regarding its effectiveness, contributing to its underutilization by physicians.
View Article and Find Full Text PDFComparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.
Eur Rev Med Pharmacol Sci
December 2023
Department of Health Management Center, Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang City, Hunan Province, China.
Objective: Febuxostat and benzbromarone are two common drugs for the treatment of gout, but the clinical efficacy of these two drugs is controversial. This meta-analysis aimed to compare the efficacy of febuxostat and benzbromarone in the treatment of gout.
Materials And Methods: PubMed, Embase, and the Cochrane Library were searched for articles related to febuxostat and benzbromarone in the treatment of gout from inception to January 7, 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!